Core Laboratories NV (CLB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Core Laboratories NV stock (CLB) is currently trading at $15.71. Core Laboratories NV PE ratio is 23.84. Core Laboratories NV PS ratio (Price-to-Sales) is 1.44. Analyst consensus price target for CLB is $15.83. WallStSmart rates CLB as Underperform.
- CLB PE ratio analysis and historical PE chart
- CLB PS ratio (Price-to-Sales) history and trend
- CLB intrinsic value — DCF, Graham Number, EPV models
- CLB stock price prediction 2025 2026 2027 2028 2029 2030
- CLB fair value vs current price
- CLB insider transactions and insider buying
- Is CLB undervalued or overvalued?
- Core Laboratories NV financial analysis — revenue, earnings, cash flow
- CLB Piotroski F-Score and Altman Z-Score
- CLB analyst price target and Smart Rating
Core Laboratories NV
📊 No data available
Try selecting a different time range
CLB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Core Laboratories NV (CLB)
CLB trades 310% above its Graham fair value of $4.62, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Core Laboratories NV (CLB) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around eps growth. Fundamentals are solid but monitor weak areas for improvement.
Core Laboratories NV (CLB) Key Strengths (2)
111.35% of shares held by major funds and institutions
Paying $1.44 for every $1 of annual revenue
Supporting Valuation Data
Core Laboratories NV (CLB) Areas to Watch (8)
Earnings declining -3.20%, profits shrinking
Thin operating margins with cost pressures present
Modest revenue growth at 7.00%
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Fairly priced relative to book value
Supporting Valuation Data
Core Laboratories NV (CLB) Detailed Analysis Report
Overall Assessment
This company scores 52/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.0/10) while 8 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.44) suggest the stock is attractively priced.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (1.67), Price/Book (2.70) suggest expensive pricing. Growth concerns include Revenue Growth at 7.00%, EPS Growth at -3.20%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.10%, Operating Margin at 11.50%, Profit Margin at 6.04%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Price/Sales) and negatives (EPS Growth, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLB's Price-to-Sales ratio of 1.44x trades at a deep discount to its historical average of 6.56x (2th percentile). The current valuation is 88% below its historical high of 11.61x set in Oct 2007, and 2% above its historical low of 1.41x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Core Laboratories NV (CLB) · ENERGY › OIL & GAS EQUIPMENT & SERVICES
The Big Picture
Core Laboratories NV operates as a stable business with moderate growth and solid fundamentals. Revenue reached 527M with 7% growth year-over-year. Profit margins are thin at 6.0%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 4M in free cash flow and 8M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Core Laboratories NV push profit margins above 15% as the business scales?
Debt management: total debt of 167M is significantly higher than cash (26M). Monitor refinancing risk.
Sector dynamics: monitor OIL & GAS EQUIPMENT & SERVICES industry trends, competitive moves, and regulatory changes that could impact Core Laboratories NV.
Bottom Line
Core Laboratories NV offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Core Laboratories NV(CLB)
NYSE
ENERGY
OIL & GAS EQUIPMENT & SERVICES
USA
Core Laboratories NV (CLB) is a leading provider of specialized reservoir optimization services and products for the oil and gas industry, dedicated to enhancing reservoir characterization and management. By leveraging advanced technologies and proprietary data analytics, the company significantly improves extraction efficiency and boosts production yields for its clients. With a strong commitment to innovation and sustainability, Core Laboratories assists clients in effectively addressing the complexities of hydrocarbon recovery. Positioned with a global footprint, CLB is well-equipped to seize emerging growth opportunities and navigate the dynamic energy landscape.